Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL5 weekly somapacitan versus daily Norditropin in short children born small for gestational age
MOH_2019-05-07_006036Phase 2Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of somapacitan and somatropin in Short stature in children born small for gestational age (5 arms), sponsored by Novo Nordisk. Started Apr 2019; status: active, not recruiting.
02
Drugs
somapacitansomatropin
03
Conditions
Short stature in children born small for gestational age
Beyond the preview
Go deeper on MOH_2019-05-07_006036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-07_006036.